Background Targeted therapies in metastatic renal cell carcinoma (mRCC) have been
approved based on registration clinical trials that have strict eligibility criteria. The clinical …

BACKGROUND. The majority of metastatic renal cell carcinoma (mRCC) clinical trials that
examined targeted agents used progression‐free survival (PFS) as the primary endpoint …

Background: Vascular endothelial growth factor (VEGF) inhibitors, including targeted
therapy with tyrosine kinase inhibitors (TKIs) and the angiogenesis inhibitor bevacizumab …

Introduction Because “real-life” patients often do not meet the strict eligibility criteria of
clinical trials, we assessed the trial eligibility of patients with advanced or metastatic renal …

Purpose: Although narrow eligibility criteria improve the internal validity of clinical trials, they
may result in differences between study populations and real-world patients, threatening …

Objective The optimal sequencing of targeted therapies for metastatic renal cell carcinoma
(mRCC) is unknown. Observational studies with a variety of designs have reported differing …

Aim To evaluate the implementation of targeted therapy on overall survival (OS) in a
complete national cohort of patients with metastatic renal cell carcinoma (mRCC). Methods …

Background Recent phase III studies of targeted agents for metastatic renal cell carcinoma
(mRCC) have generated median survival estimates that far exceed those observed during …

Context No head-to-head clinical trials compare contemporary first-line therapies for
metastatic renal cell carcinoma (mRCC). A network meta-analysis provides an approach for …

Background It is currently not known whether treatment with anti–vascular endothelial
growth factor agents for metastatic renal cell carcinoma (mRCC) can be safely discontinued …